Humana HUM · NYSE
$412.39 -0.19% (-$0.77)
Summary
42 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 25% this fiscal year.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- Earnings per share fell by 24% a year over the last 3 years.
- You pay 38.8 USD for 1 USD of yearly profit, a lot for its sector.
- Out of every 100 USD of revenue, only 0.9 USD is left as net profit.
- It earns only 4.5 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.8 USD for 1 USD of yearly profit. Over the last five years it was 23.6 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 25%. Earnings per share fell by 24% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 86 USD
- Sales and administration 12 USD
- Taxes and other 0.5 USD
- Net profit 0.9 USD
Net profit, industry median (Medical - Healthcare Plans) 2.3 USD
Out of every 100 USD of revenue, 0.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.86%
- Paid out of profit
- 33%
You receive $3.54 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 21
- Hold 22
- Sell 1
Today's price within the analysts' price targets
The average target of $467.05 is 13% above today's price. 48% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Insurance Segment 85%
- CenterWell Segment 15%
By region
The company reports no revenue by region.
Insurance Segment brings in 85% of revenue.
Segments in detail